Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041992 | 1.00 | GRIN1 (0.41) | GRIN1GRIN2BSRCLTA4HHTR7 | |
| SCHEMBL5047712 | 0.86 | MMP2 (0.44) | GRIN1GRIN2BHTR7MEN1KMT2A | |
| SCHEMBL5047717 | 0.86 | MMP2 (0.44) | GRIN1GRIN2BHTR7MEN1KMT2A | |
| SCHEMBL5505396 | 0.86 | MMP2 (0.44) | GRIN1GRIN2BHTR7MEN1KMT2A | |
| SCHEMBL14300258 | 0.86 | GRIN1 (0.41) | GRIN1GRIN2BLTA4HHTR7MEN1 | |
| SCHEMBL5038040 | 0.85 | KMT2A (0.41) | GRIN1GRIN2BLTA4HHTR7MEN1 | |
| SCHEMBL5133156 | 0.83 | HTR7 (0.42) | GRIN1GRIN2BLTA4HHTR7MEN1 | |
| SCHEMBL5133153 | 0.83 | HTR7 (0.42) | GRIN1GRIN2BLTA4HHTR7MEN1 | |
| SCHEMBL7653612 | 0.83 | KMT2A (0.39) | GRIN1GRIN2BLTA4HHTR7MEN1 | |
| SCHEMBL5041905 | 0.80 | GAA (0.37) | GRIN1GRIN2BLTA4HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313703-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | claimed |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | EVOTEC INTERNATIONAL GMBH (DE) | 2002-04-04 | — | — | US | claimed |
| WO-2002016321-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | claimed |
| EP-1313703-B1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| EP-1313703-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-6407235-B1 | A NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR-SUBTYPE SELECTIVE BLOCKERS; PRODRUGS HAVE IMPROVED SOLUBILITY AND ARE HYDROLYZED IN VIVO; FOR EXAMPLE, THE 4-AMINOMETHYL-BENZOIC ACID ESTER OF THE PHENOL, OR THE PHOSPHATE ESTER | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | EVOTEC INTERNATIONAL GMBH (DE) | 2002-04-04 | — | — | US | disclosed |
| WO-2002016321-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | HAO2, CYP2B6, CBR1 | GRIN1 3691/4885GRIN2B 2694/4885SRC 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.